Literature DB >> 33479342

Positive expectations predict improved mental-health outcomes linked to psychedelic microdosing.

L S Kaertner1, M B Steinborn2, H Kettner3, M J Spriggs3, L Roseman3, T Buchborn3, M Balaet4, C Timmermann3, D Erritzoe3, R L Carhart-Harris3.   

Abstract

Psychedelic microdosing describes the ingestion of near-threshold perceptible doses of classic psychedelic substances. Anecdotal reports and observational studies suggest that microdosing may promote positive mood and well-being, but recent placebo-controlled studies failed to find compelling evidence for this. The present study collected web-based mental health and related data using a prospective (before, during and after) design. Individuals planning a weekly microdosing regimen completed surveys at strategic timepoints, spanning a core four-week test period. Eighty-one participants completed the primary study endpoint. Results revealed increased self-reported psychological well-being, emotional stability and reductions in state anxiety and depressive symptoms at the four-week primary endpoint, plus increases in psychological resilience, social connectedness, agreeableness, nature relatedness and aspects of psychological flexibility. However, positive expectancy scores at baseline predicted subsequent improvements in well-being, suggestive of a significant placebo response. This study highlights a role for positive expectancy in predicting positive outcomes following psychedelic microdosing and cautions against zealous inferences on its putative therapeutic value.

Entities:  

Year:  2021        PMID: 33479342      PMCID: PMC7820236          DOI: 10.1038/s41598-021-81446-7

Source DB:  PubMed          Journal:  Sci Rep        ISSN: 2045-2322            Impact factor:   4.379


  65 in total

1.  The brief experiential avoidance questionnaire: development and initial validation.

Authors:  Wakiza Gámez; Michael Chmielewski; Roman Kotov; Camilo Ruggero; Nadia Suzuki; David Watson
Journal:  Psychol Assess       Date:  2013-09-23

Review 2.  Human hallucinogen research: guidelines for safety.

Authors:  Mw Johnson; Wa Richards; Rr Griffiths
Journal:  J Psychopharmacol       Date:  2008-07-01       Impact factor: 4.153

3.  Placebo and its evil twin, nocebo.

Authors:  Michael Glick
Journal:  J Am Dent Assoc       Date:  2016-04       Impact factor: 3.634

4.  Survey study of challenging experiences after ingesting psilocybin mushrooms: Acute and enduring positive and negative consequences.

Authors:  Theresa M Carbonaro; Matthew P Bradstreet; Frederick S Barrett; Katherine A MacLean; Robert Jesse; Matthew W Johnson; Roland R Griffiths
Journal:  J Psychopharmacol       Date:  2016-08-30       Impact factor: 4.153

5.  Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial.

Authors:  Roland R Griffiths; Matthew W Johnson; Michael A Carducci; Annie Umbricht; William A Richards; Brian D Richards; Mary P Cosimano; Margaret A Klinedinst
Journal:  J Psychopharmacol       Date:  2016-12       Impact factor: 4.153

6.  Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: a randomized controlled trial.

Authors:  Stephen Ross; Anthony Bossis; Jeffrey Guss; Gabrielle Agin-Liebes; Tara Malone; Barry Cohen; Sarah E Mennenga; Alexander Belser; Krystallia Kalliontzi; James Babb; Zhe Su; Patricia Corby; Brian L Schmidt
Journal:  J Psychopharmacol       Date:  2016-12       Impact factor: 4.153

7.  Chronic, Intermittent Microdoses of the Psychedelic N,N-Dimethyltryptamine (DMT) Produce Positive Effects on Mood and Anxiety in Rodents.

Authors:  Lindsay P Cameron; Charlie J Benson; Brian C DeFelice; Oliver Fiehn; David E Olson
Journal:  ACS Chem Neurosci       Date:  2019-03-04       Impact factor: 4.418

8.  LSD enhances suggestibility in healthy volunteers.

Authors:  R L Carhart-Harris; M Kaelen; M G Whalley; M Bolstridge; A Feilding; D J Nutt
Journal:  Psychopharmacology (Berl)       Date:  2014-09-23       Impact factor: 4.530

9.  Quality of Acute Psychedelic Experience Predicts Therapeutic Efficacy of Psilocybin for Treatment-Resistant Depression.

Authors:  Leor Roseman; David J Nutt; Robin L Carhart-Harris
Journal:  Front Pharmacol       Date:  2018-01-17       Impact factor: 5.810

10.  The Meaning-Enhancing Properties of Psychedelics and Their Mediator Role in Psychedelic Therapy, Spirituality, and Creativity.

Authors:  Ido Hartogsohn
Journal:  Front Neurosci       Date:  2018-03-06       Impact factor: 4.677

View more
  16 in total

1.  Natural language signatures of psilocybin microdosing.

Authors:  Camila Sanz; Federico Cavanna; Stephanie Muller; Laura de la Fuente; Federico Zamberlan; Matías Palmucci; Lucie Janeckova; Martin Kuchar; Facundo Carrillo; Adolfo M García; Carla Pallavicini; Enzo Tagliazucchi
Journal:  Psychopharmacology (Berl)       Date:  2022-06-09       Impact factor: 4.415

2.  Psilocybin microdosers demonstrate greater observed improvements in mood and mental health at one month relative to non-microdosing controls.

Authors:  Joseph M Rootman; Maggie Kiraga; Pamela Kryskow; Kalin Harvey; Paul Stamets; Eesmyal Santos-Brault; Kim P C Kuypers; Zach Walsh
Journal:  Sci Rep       Date:  2022-06-30       Impact factor: 4.996

Review 3.  Molecular targets of psychedelic-induced plasticity.

Authors:  Alaina M Jaster; Mario de la Fuente Revenga; Javier González-Maeso
Journal:  J Neurochem       Date:  2021-11-15       Impact factor: 5.546

4.  Restoration of Attention by Rest in a Multitasking World: Theory, Methodology, and Empirical Evidence.

Authors:  Frank Schumann; Michael B Steinborn; Jens Kürten; Liyu Cao; Barbara Friederike Händel; Lynn Huestegge
Journal:  Front Psychol       Date:  2022-04-01

5.  MDLSD: study protocol for a randomised, double-masked, placebo-controlled trial of repeated microdoses of LSD in healthy volunteers.

Authors:  Robin J Murphy; Rachael L Sumner; William Evans; David Menkes; Ingo Lambrecht; Rhys Ponton; Frederick Sundram; Nicholas Hoeh; Sanya Ram; Lisa Reynolds; Suresh Muthukumaraswamy
Journal:  Trials       Date:  2021-04-23       Impact factor: 2.279

Review 6.  1H Nuclear Magnetic Resonance: A Future Approach to the Metabolic Profiling of Psychedelics in Human Biofluids?

Authors:  Sylvana Vilca-Melendez; Malin V Uthaug; Julian L Griffin
Journal:  Front Psychiatry       Date:  2021-12-13       Impact factor: 4.157

7.  Prolonged epigenomic and synaptic plasticity alterations following single exposure to a psychedelic in mice.

Authors:  Mario de la Fuente Revenga; Bohan Zhu; Christopher A Guevara; Lynette B Naler; Justin M Saunders; Zirui Zhou; Rudy Toneatti; Salvador Sierra; Jennifer T Wolstenholme; Patrick M Beardsley; George W Huntley; Chang Lu; Javier González-Maeso
Journal:  Cell Rep       Date:  2021-10-19       Impact factor: 9.423

8.  Psilocybin microdosing does not affect emotion-related symptoms and processing: A preregistered field and lab-based study.

Authors:  Josephine Marschall; George Fejer; Pascal Lempe; Luisa Prochazkova; Martin Kuchar; Katerina Hajkova; Michiel van Elk
Journal:  J Psychopharmacol       Date:  2021-12-17       Impact factor: 4.153

9.  How Psychedelic-Assisted Treatment Works in the Bayesian Brain.

Authors:  Daniel Villiger
Journal:  Front Psychiatry       Date:  2022-03-08       Impact factor: 4.157

10.  Does Psychedelic Therapy Have a Transdiagnostic Action and Prophylactic Potential?

Authors:  Rita Kočárová; Jiří Horáček; Robin Carhart-Harris
Journal:  Front Psychiatry       Date:  2021-07-19       Impact factor: 4.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.